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The tumor promoter 12-O-tetra-decanoylphorbol-13-acetate (TPA)
has been defined by its ability to promote tumorigenesis on
carcinogen-initiated mouse skin. Activation of Wnt/β-catenin signaling
has a decisive role in mouse skin carcinogenesis, but it remains unclear
how TPA activates Wnt/β-catenin signaling in mouse skin carcinogen-
esis. Here, we found that TPA could enhanceWnt/β-catenin signaling in
a casein kinase 1 (CK1) e/δ-dependent manner. TPA stabilized CK1e and
enhanced its kinase activity. TPA further induced the phosphorylation
of LRP6 at Thr1479 and Ser1490 and the formation of a CK1e–LRP6–
axin1 complex, leading to an increase in cytosolic β-catenin. Moreover,
TPA increased the association of β-catenin with TCF4E in a CK1e/δ-
dependent way, resulting in the activation of Wnt target genes. Con-
sistently, treatmentwith a selective CK1e/δ inhibitor SR3029 suppressed
TPA-induced skin tumor formation in vivo, probably through blocking
Wnt/β-catenin signaling. Taken together, our study has identified a
pathway by which TPA activates Wnt/β-catenin signaling.
TPA | CK1 | LRP6 | Wnt/β-catenin signaling | two-stage skin chemical
carcinogenesis
The Wnt/β-catenin signaling pathway plays a crucial role inembryonic development, stem cell self-renewal, and tumori-
genesis (1–4). In the absence of Wnt proteins, β-catenin is con-
stantly degraded by a destruction complex containing the
scaffolding protein axin, the adenomatosis polyposis coli (APC)
protein, the enzyme glycogen synthase kinase-3β (GSK3β), and
casein kinase 1 (CK1). The Wnt/β-catenin signaling cascade is
initiated when the secreted Wnt proteins bind to the low-density
lipoprotein receptor-related protein 5/6 (LRP5/6) and a member
of the Frizzled (Fzd) family (2, 5). Subsequently, CK1 is acti-
vated and phosphorylates Dishevelled (Dvl) (6). Receptor com-
plexes further cluster on platforms of oligomerized Dvl, leading
to the formation of LRP6 signalosomes (7, 8). Receptor clus-
tering triggers phosphorylation of LRP6 by multiple CK1 mem-
bers following priming by GSK3β and recruits the axin complex
to signalosomes (8). As a consequence, phosphorylation of
β-catenin is inhibited. Unphosphorylated β-catenin accumulates
in the cytoplasm and translocates into the nucleus, where it binds
transcription factors of the T-cell factor/lymphoid enhancing
factor (TCF/LEF) family and recruits the transcriptional Kat3
coactivators p300 and/or CREB-binding protein, finally leading
to the expression of Wnt target genes (9, 10).
The CK1 family of serine/threonine kinases consists of six
human isoforms (α, δ, e, γ1, γ2, and γ3). All members share a
highly conserved amino-terminal kinase domain. Among them,
CK1e and CK1δ display the highest consensus, with a 98% se-
quence identity in their kinase domain and 53% identity in their
C-terminal regulatory domain (11, 12). CK1 members phos-
phorylate several key regulatory molecules in the Wnt/β-catenin
signaling pathway and exert dual functions, acting either as in-
hibitors or activators of the pathway (13, 14). In the β-catenin
destruction complex, CK1α phosphorylates β-catenin at Ser45
and primes β-catenin for further phosphorylation by GSK3β and
subsequent degradation (10). Moreover, CK1e and CK1δ are
able to phosphorylate APC in cooperation with GSK3β, resulting
in an increase in affinity of APC to β-catenin and its ability to
down-regulate β-catenin (6). Upon Wnt stimulation, CK1e ac-
tivity is rapidly up-regulated and phosphorylates Dvl at multiple
sites (15, 16), which is required for LRP6 signalosome formation
and LRP6 phosphorylation at Thr1479 and Ser1490 (8). CK1e
can also phosphorylate TCF3, thereby increasing its binding to
β-catenin (17).
TPA (12-O-tetra-decanoylphorbol-13-acetate) is generally
known for its tumor-promoting activity in two-stage skin chem-
ical carcinogenesis (18). It specifically induces clonal expansion
of initiated cells carrying activated ras oncogenes (19), resulting
in tumor development. Although protein kinase C (PKC) family
members have been identified as the main targets of TPA (20),
their role in tumor promotion remains controversial (21). So far,
clinical trials using PKC inhibitors for the treatment of cancer
have been ineffective (21, 22). A meta-analysis of several clinical
trials for non-small-cell lung carcinomas revealed worsened pa-
tient outcome when PKC inhibitors were combined with che-
motherapy compared with chemotherapy alone (23). The results
from other clinical trials also showed that targeting PKC in
cancer is not an effective approach to therapy (24, 25). Fur-
thermore, Antal et al. (21) recently observed that cancer-
associated mutations in PKC are generally loss-of-function,
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suggesting that PKC isozymes generally function as tumor sup-
pressors. However, the PKC family is not the sole receptor for
the phorbol esters. Several non-PKC proteins have been identi-
fied as new phorbol ester receptors, including protein kinase D (26),
diacylglycerol kinases (27, 28), guanine nucleotide exchange factors
for small GTPases (RasGRPs) (29), GTPase-activating proteins
(chimaerin Rac-GAPs) (30), and components of the synaptic vesicle
fusion protein complex (Munc-13 isoforms) (31). The discovery of
these novel phorbol ester receptors raises the hypothesis that the
tumor-promoting effect of various phorbol esters may proceed
through PKC-independent pathways.
In two-stage skin chemical carcinogenesis, a single topical
application of a carcinogen DMBA (7,12-dimethylbenz[a]an-
thracene) on the mouse skin, followed by repeated applications
of TPA, results in the formation of benign skin papillomas, of
which some progress into invasive squamous cell carcinomas (18,
32, 33). H-ras mutation is a hallmark of DMBA/TPA-induced
skin papillomas (34). Mutations of the H-ras oncogene activate
several downstream pathways, including Ras/Raf/ MAPK/ERK
and PI3K/Akt (35, 36). Activation of PKCs by TPA may also lead
to enhanced Ras/Raf-1/MAP kinase signaling (37). Additionally,
TPA can induce activation of AP-1 and NF-κB transcription
factors in mouse skin through effects on ERK, c-Jun NH2-
terminal kinase, Akt, and p38 MAPK (38).
The Wnt/β-catenin signaling pathway plays a decisive role in
skin tumorigenesis (39). Transgenic mice expressing a constitu-
tively activated version of β-catenin develop skin tumors re-
sembling pilomatricomas (40). Keratinocyte-specific knockout of
the Ctnnb1 gene (encoding β-catenin) prevents DMBA/TPA-
induced tumorigenesis in mouse skin (41, 42). The ablation of
β-catenin function in established DMBA/TPA-induced tumors
leads to their complete regression (43). Moreover, DMBA/TPA-
induced tumors showed cytoplasmic and nuclear accumulation of
β-catenin and up-regulation of Wnt target genes (c-myc and c-
jun). TCF4 was found to be a major effector in Wnt/β-catenin
signaling in mouse skin carcinogenesis (44). Apparently, TPA-
induced tumorigenesis is associated with activation of Wnt/
β-catenin signaling. However, it is not yet clear how TPA acti-
vates Wnt/β-catenin signaling in the two-stage carcinogenesis
model. In the present study, we found that TPA stabilized CK1e
and enhanced its kinase activity. TPA further induced the
phosphorylation of LRP6 and the formation of a CK1e–LRP6–
axin1 complex, thus bypassing the requirement for a Wnt–Fzd–
Dvl complex. Furthermore, TPA treatment promoted the asso-
ciation of β-catenin with TCF4E in a CK1e/δ-dependent manner.
Importantly, a specific CK1e/δ inhibitor SR3029 blocked DMBA/
TPA-induced skin tumorigenesis in vivo, probably through in-
hibition of Wnt/β-catenin signaling.
Results
TPA Enhances Wnt/β-Catenin Signaling Activated by CK1e. The cal-
cium ionophore ionomycin exerts antagonistic activity on the
Wnt/β-catenin pathway by increasing intracellular calcium levels
(45). The elevation of intracellular calcium levels may activate
PKC. We compared the effects of ionomycin and the PKC ac-
tivator TPA on Wnt/β-catenin signaling. The SuperTopFlash
reporter system was used to determine the activation of Wnt/
β-catenin signaling in response to ionomycin and TPA. The
SuperTopFlash reporter was transfected into HEK293T cells
along with Wnt1, Wnt1/LRP6, Wnt3/LRP6, Dvl2, and CK1e
expression plasmids, respectively. As expected, ionomycin and
TPA inhibited Wnt signaling activated by Wnt1 (Fig. 1 A and D),
Wnt1/LRP6 (SI Appendix, Fig. S1 A and D), Wnt3/LRP6 (SI
Appendix, Fig. S1 B and E), and Dvl2 (SI Appendix, Fig. S1 C and
F) in a dose-dependent manner, respectively. Moreover, the in-
creased SuperTopFlash activity induced by Wnt3A-conditioned
medium (Wnt3A-CM) was dose-dependently blocked by either
ionomycin or TPA (Fig. 1 B and E). Surprisingly, ionomycin and
TPA differentially regulated the transcriptional activity of the
SuperTopFlash reporter in HEK293T cells transfected with a
CK1e expression plasmid. TPA dose-dependently enhanced
CK1e-mediated reporter transcription, while ionomycin re-
pressed this effect (Fig. 1 C and F). To test whether TPA has any
effect on the expression of Wnt target genes in a CK1e-
dependent manner, the CK1e expression plasmid was trans-
fected in HEK293T cells. Cells were then incubated overnight
with 10 nM TPA. Quantitative PCR was performed to detect the
mRNA expression of Wnt target genes DKK1, Fra-1, and Fosb.
TPA significantly increased mRNA expression levels of Wnt
target genes DKK1, Fra-1, and Fosb in a CK1e-dependent way
(SI Appendix, Fig. S2A). These results suggest that TPA may
have a positive regulatory effect on CK1e-mediated Wnt sig-
naling via a calcium/PKC-independent mechanism.
To examine the effect of TPA on other signaling pathways,
transfection assays were performed using an NFAT reporter
(NFAT-Luc) and a Hippo reporter (8 × GTIIC-Luc). The ex-
pression plasmids encoding NFATc1 and YAP were used to
activate the NFAT and Hippo signaling pathways in HEK293T
Fig. 1. TPA enhances Wnt/β-catenin signaling activated by CK1. (A) A
SuperTopFlash reporter gene was transfected into HEK293T cells together
with empty vector or Wnt1 expression plasmid. The transfected cells were
treated with vehicle or the indicated concentrations of ionomycin before
being assayed for luciferase activity. (B) The SuperTopFlash reporter gene
was transfected into HEK293T cells, after which the cells were treated with
control or Wnt3A-CM. The cells were treated with vehicle or increasing
concentrations of ionomycin as indicated. (C) HEK293T cells were transfected
with the SuperTopFlash reporter gene and empty vector or an expression
plasmid for CK1e. The cells were incubated with vehicle or increasing con-
centrations of ionomycin as indicated. (D) Similar to A except that the in-
dicated concentrations of TPA were used. (E) Similar to B except that the
indicated concentrations of TPA were used. (F) Similar to C except that the
indicated concentrations of TPA were used. The luciferase values were
normalized to β-gal activities. Results are expressed as fold induction com-
pared with empty vector control. The results were the average from at least
three independent experiments done by duplicates, n ≥ 6.
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cells, respectively. As shown in SI Appendix, Fig. S2 B and C,
TPA had no effect on the luciferase activity of NFAT-Luc and
8 × GTIIC-Luc (SI Appendix, Fig. S2 B and C).
Effects of Other Phorbol Esters and PKC Modulators on CK1e-
Mediated Wnt Signaling. We examined the effects of other phorbol
esters on CK1e-mediated Wnt signaling. Similar to TPA (SI Ap-
pendix, Fig. S3A), phorbol 12, 13-didecanoate (PDD) and phorbol
12, 13-dibutyrate (PDBu) increased the luciferase activity of a
SuperTopFlash reporter in HEK293T cells overexpressing CK1e in a
dose-dependent fashion (SI Appendix, Fig. S3 B and C). In con-
trast, a non-tumor-promoting phorbol ester, 4α-PDD, had no ef-
fect on CK1e-mediated Wnt signaling (SI Appendix, Fig. S3D).
Some PKC modulators, including three PKC activators (DOG,
DHI, and OAG) and two PKC inhibitors (NPC15437 dihydrochloride
and Gö 6976) were used to explore the role of PKC in CK1-mediated
activation of Wnt signaling in response to TPA. Unlike TPA, none of
the PKC activators increased SuperTopFlash reporter activity in cells
overexpressing CK1e (SI Appendix, Fig. S4 A–C), while two PKC
inhibitors showed little inhibitory effect on reporter gene transcription
mediated by CK1e (SI Appendix, Fig. S4 D and E). These results
indicate that PKC may not be involved in CK1e-mediated activation
of Wnt signaling in response to TPA.
CK1e and CK1δ Are Major Effectors of TPA-Induced Wnt Signaling. To
determine which member of the CK1 family plays a more im-
portant role in TPA-induced Wnt signaling, HEK293T cells were
transfected with a SuperTopFlash reporter plasmid together with
CK1α, CK1γ, CK1e, and CK1δ expression plasmids, respectively.
Treatment with TPA dramatically increased transcriptional activity
mediated by either CK1e or CK1δ in a dose-dependent manner,
whereas TPA had much weaker effect on CK1α-mediated tran-
scription (Fig. 2A). TPA treatment had no effect on CK1γ-mediated
transcription. The immunoblotting results with an anti-Flag antibody
showed that TPA treatment dose-dependently increased the expres-
sion of CK1e and CK1δ, while TPA had negligible effects on the
expression of CK1α and CK1γ (Fig. 2B). These results indicate that
CK1e and CK1δ are major effectors of TPA-induced Wnt signaling
and TPA may regulate the protein expression of CK1e and CK1δ.
To validate the specific role of CK1e/δ in TPA-induced Wnt
signaling, dominant negative mutants of CK1e/δ and specific CK1
inhibitors were used to test the effect of TPA on CK1e/δ-mediated
Fig. 2. CK1e and CK1δ are major effectors of TPA-induced Wnt signaling. (A) HEK293T cells were transfected with the SuperTopFlash reporter gene together
with empty vector or expression plasmids encoding CK1α, CK1γ, CK1e, and CK1δ, respectively. The transfected cells were treated with vehicle or increasing
concentrations of TPA as indicated. (B) Protein expression of CK1 isoforms and GAPDH were detected by immunoblotting using anti-Flag and anti-GAPDH
antibodies. Data shown were representative of three independent experiments. The protein levels of CK1 isoforms were quantitated by densitometry and
normalized to GAPDH. Quantitated results were displayed at the right. (C) The SuperTopFlash reporter gene was transfected into HEK293T cells together with
50 ng wild-type CK1e, either alone or in combination with increasing amounts of dominant negative construct (0, 25, 50, 100, and 200 ng) and incubated with
or without 10 nM TPA. (D) Similar to C except that wild-type CK1δ and its dominant negative construct were used. (E) HEK293T cells cotransfected with the
SuperTopFlash reporter gene and CK1e expression vector were incubated with or without 10 nM TPA in the presence of increasing concentrations of SR3029
(0, 15, 30, 60, and 120 nM). (F) Similar to E except that CK1δ expression vector was used. (G) Similar to E except that increasing concentrations of PF670462 (0,
0.25, 0.5, 1, and 2 μM) were used. (H) Similar to F except that increasing concentrations of PF670462 (0, 0.25, 0.5, 1, and 2 μM) were used. The luciferase
activities were measured and values were normalized to β-gal activity. Results are expressed as fold induction compared with empty vector control. The results
were the average from at least three independent experiments done by duplicates (n ≥ 6).
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transcription. Increasing concentrations of dominant negative
mutants of CK1e (Fig. 2C) or CK1δ (Fig. 2D) blocked wild-type
CK1e/δ-mediated transcriptional activity of a SuperTopFlash re-
porter in response to TPA. Furthermore, specific CK1e/δ in-
hibitors SR3029 and PF670462 markedly inhibited TPA-induced
transcriptional activation in the presence of CK1e or CK1δ
(Fig. 2 E–H).
TPA Regulates the Expression and Subcellular Localization of CK1e
and CK1δ. We next examined the effect of TPA on expression
levels of the CK1e and CK1δ proteins in HEK293T and melanoma
UACC903 cells. Western blot analyses showed that TPA aug-
mented expression of endogenous CK1e and CK1δ in a time- and
dose-dependent manner in both cell lines (Fig. 3 A and B). We then
determined if TPA affects the half-life of CK1e and CK1δ proteins.
Protein translation was inhibited by cycloheximide (CHX). The
results showed that treatment with CHX reduced the levels of en-
dogenous CK1e and CK1δ in a time-dependent manner in HEK293T
cells, and addition of TPA increased the half-life of CK1e and
CK1δ proteins (Fig. 3C). Treatment with the proteasome in-
hibitor MG132 also enhanced TPA-induced accumulation of
CK1e and CK1δ in both cell lines (Fig. 3D), suggesting that the
Fig. 3. TPA regulates the expression and subcellular localization of CK1e and CK1δ. (A) HEK293T and UACC903 cells were incubatedwith TPA at increasing concentrations
(0, 2, 10, 50, 100, and 200 nM). The whole-cell extracts were analyzed by immunoblotting using the indicated antibodies. The protein levels of CK1e and CK1δ were
quantitated by densitometry and normalized to Lamin B1. Quantitated results are displayed (Bottom). (B) HEK293T and UACC903 cells were incubated with 10 nM TPA for
the indicated time period. The expression of CK1e and CK1δ proteins were assessed by immunoblotting. The protein levels of CK1e and CK1δ were quantitated by
densitometry and normalized to Lamin B1. Quantitated results are displayed (Bottom). (C) HEK293T cells were pretreated with 10 nM TPA for 2 h before 100 μg/mL CHX
was added. The cells were harvested after CHX treatment for the indicated times (0, 2, 4, and 6 h) followed by immunoblotting. The protein levels of CK1e and CK1δ were
quantitated by densitometry and normalized to GAPDH. Quantitated results were plotted against indicated time periods to dynamic changes and are displayed (Bottom).
*P < 0.05, **P < 0.01 versus vehicle control (Student’s t test, n = 3). (D) HEK293T and UACC903 cells were incubated with increasing concentrations of TPA (0, 100, and
200 nM) for 6 h and then were treated with 10 μMMG132 for 1 h. The cells were harvested and the levels of CK1e and CK1δ proteins were detected by immunoblotting.
The protein levels of CK1e and CK1δ were quantitated by densitometry and normalized to Lamin B1. Quantitated results are displayed (Bottom). (E) HEK293T cells
cotransfected with Flag-CK1e/δ and myc-ubiquitin (Ub) expression vectors were incubated with or without the indicated concentrations of TPA for 18 h before treatment
with 10 μMMG132 for 6 h. Cell lysates were subjected to immunoprecipitation using anti-FlagM2 Sepharose (Sigma) followed byWestern blot using specific antibodies as
indicated. Ubiquitination of CK1e and CK1δ protein was quantitated by densitometry from three independent experiments and normalized to Flag levels. Quantitated
results were plotted against indicated concentrations of TPA to ubiquitination levels. *P < 0.05, **P < 0.01 versus the corresponding vehicle control (Student’s t test, n = 3).
(F) HEK293T cells and UACC903 cells were treated with 10 nM TPA for 6 h, and subcellular fractions were isolated from the whole-cell extracts by Subcellular Protein
Fractionation Kit according to the manufacturer’s protocol (Thermo). The protein levels were detected by immunoblotting using specific antibodies as indicated. Data
shown are representative from three independent experiments. Protein levels were quantified by densitometry and normalized to the corresponding loading control. CE,
cytoplasmic extract; ME, membrane extract; NE, nuclear extract. *P < 0.05 versus the corresponding vehicle control (Student’s t test, n = 3).
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increased levels of CK1e and CK1δ may be due to decreased
degradation. In contrast, TPA had negligible effects on the half-
life of dominant negative CK1e in HEK293T cells transfected
with dominant negative CK1e (SI Appendix, Fig. S5A).
To test the effect of TPA on the ubiquitination of CK1e and
CK1δ, Flag-tagged CK1e/δ and myc-tagged ubiquitin expression
vectors were cotransfected into HEK293T cells. Cells were in-
cubated with 5 nM and 10 nM TPA for 18 h before treatment
with 10 μM MG132 as indicated in Fig. 3E. The cell lysates were
subjected to immunoprecipitation using anti-Flag antibody fol-
lowed by separation on SDS/PAGE and immunoblotting analysis
with anti-ubiquitin and anti-Flag antibodies. As shown in Fig. 3E,
TPA significantly decreased the ubiquitination of CK1e and
CK1δ (Fig. 3E). However, TPA did not affect the ubiquitination
of dominant negative CK1e/δ (SI Appendix, Fig. S5B). These
results suggest that TPA negatively mediates the ubiquitination
of CK1e and CK1δ.
To determine whether TPA can influence subcellular locali-
zation of CK1e and CK1δ, we examined the subcellular distri-
bution of endogenous CK1e and CK1δ after TPA treatment.
HEK293T and UACC903 cells were incubated with 10 nM TPA
for 6 h, and cell fractions were subjected to Western blot anal-
ysis. The protein levels of subcellular fractions were quantitated
by densitometry. The results showed that TPA induced an in-
crease in the protein levels of CK1e and CK1δ in the membrane,
nuclear, and cytoplasmic fractions in HEK293T and UACC903 cells,
Fig. 4. TPA induces the phosphorylation of LRP6 and the formation of a CK1e–LRP6–axin1 complex. (A) HEK293T and UACC903 cells cotransfected with CK1e-
GFP and LRP6 expression vectors were treated with 10 nM TPA for 6 h. Cell lysates were analyzed by immunoblotting using specific antibodies as indicated.
The levels of phosphorylated Thr1479 and Ser1490 forms of LRP6 were quantitated by densitometry and normalized to GAPDH levels. *P < 0.05, **P <
0.01 versus vehicle control (one-way ANOVA, n = 3). Quantitated results are displayed (Bottom). (B) HEK293T and UACC903 cells transfected with a CK1e
expression plasmid were treated with or without 10 nM TPA for 6 h. The levels of phosphorylated Thr1479 and Ser1490 forms of LRP6 were quantitated by
densitometry and normalized to GAPDH levels. *P < 0.05, **P < 0.01 versus vehicle control (one-way ANOVA, n = 3). (C) UACC903 cells were incubated with
10 nM TPA in the presence or absence of 60 nM SR3029 for 6 h. The levels of phosphorylated Thr1479 and Ser1490 forms of LRP6 were quantitated by
densitometry and normalized to GAPDH levels. *P < 0.05, **P < 0.01 versus vehicle control (one-way ANOVA, n = 3). (D) HEK293T cells were transfected with
or without a Flag-CK1e expression plasmid in the absence or presence of 10 nM TPA for 6 h. Cell lysates were subjected to immunoprecipitation with ant-
LRP6 antibody followed by immunoblotting analysis using the indicated antibodies. Protein levels were quatified by densitometry and normalized to
LRP6 levels. (E) The SuperTopFlash reporter gene was transfected into HEK293T cells together with expression vectors encoding LRP6 and CK1e. Transfected
cells were incubated with increasing concentrations of TPA as indicated. (F) Similar to E except that expression vectors for LRP6 and CK1δ were used. Lu-
ciferase activity was measured and presented as fold induction compared with empty vector control. Data were collected from three independent experi-
ments done by duplicates (n = 6).
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while TPA-induced increase did not occur evenly in different frac-
tions (Fig. 3F).
TPA Decreases the Level of Phosphorylated Dvl. Wnt-induced
phosphorylation of Dvl is an essential step in Wnt/β-catenin
signaling. Dvl proteins have been shown to be CK1e/δ substrates
in vivo. Upon Wnt stimulation, CK1e/δ phosphorylates Dvl at
distinct Ser/Thr residues (6, 16). We examined the effect of
treatment with TPA on Dvl phosphorylation in HEK293T and
UACC903 cells. TPA treatment decreased the levels of phos-
phorylated Dvl2, which was visualized as a slower-migrating band
on SDS/PAGE, in both cell lines (SI Appendix, Fig. S6). The
TPA-induced decrease of phosphorylated Dvl2 might be attrib-
uted to its activation of calcium/PKC signaling since ionomycin
also caused a similar decrease in phosphorylation of Dvl2 (SI
Appendix, Fig. S6).
TPA Induces the Phosphorylation of LRP6 and the Formation of CK1e–
LRP6–Axin1 Complex. Considering the critical role of LRP6
phosphorylation in Wnt/β-catenin signaling, we examined the effect
of CK1e on TPA-induced phosphorylation of LRP6. HEK293T and
UACC903 cells were transfected with an LRP6 expression vector in
the absence or presence of an expression plasmid encoding CK1e.
As shown in Fig. 4 A and B, TPA induced the phosphorylation of
endogenous and exogenous LRP6 at Thr1479 and Ser1490 in both
cell lines, and stronger effects were observed in the cells transfected
with the CK1e expression vector (Fig. 4 A and B). Ser1490 of
LRP6 can be phosphorylated by multiple kinases, including GSK3β,
GRK5, and ERK kinases (8). A previous study showed that TPA
could induce Ser1490 LRP6 phosphorylation by activating ERK
(46). We postulate that the presence of CK1e may facilitate ERK-
mediated LRP6 phosphorylation. Consistently, the CK1 inhibitor
SR3029 dramatically blocked TPA-mediated LRP6 phosphorylation
at Thr1479 and Ser1490 in UACC903 cells (Fig. 4C).
To identify the downstream interacting partners of CK1e in
response to TPA, a Flag-tagged CK1e expression vector was
transfected into HEK293T cells. At 6 h after treatment with
10 nM TPA, cell lysates were isolated and immunoprecipitated
with anti-LRP6 antibody. As shown in Fig. 4D, overexpressing
CK1e by transfection alone enhanced the complex formation of
CK1e–LRP6–axin1, and treatment with TPA potentiated the
interaction among CK1, LRP6, and axin1 (Fig. 4D). These re-
sults suggest that TPA induces the formation of CK1e–LRP6–
axin1 multiprotein complex.
To test the effect of TPA on Wnt signaling activated by CK1e/
LRP6 or CK1δ/LRP6, HEK293T cells were transfected with the
SuperTopFlash reporter together with expression vectors encod-
ing CK1e/LRP6 and CK1δ/LRP6, respectively. As expected, TPA
enhanced reporter transcription activated by either CK1e/LRP6
(Fig. 4E) or CK1δ/LRP6 (Fig. 4F) in a dose-dependent fashion.
CK1e Phosphorylates LRP6 at Thr1479 in Vitro and TPA Enhances the
Kinase Activity of CK1e. Thr1479 residue of LRP6 is a typical ca-
sein kinase target (8). Since TPA treatment increased the in-
teraction between CK1e and LRP6, it is reasonable to assume
that CK1e may directly phosphorylate LRP6 at Thr1479. To
determine if CK1e directly phosphorylates LRP6 at Thr1479, an
in vitro kinase assay was performed. The recombinant GST-
LRP6 mini fusion protein was incubated with the purified
CK1e enzyme in a reaction buffer containing 200 μM ATP. The
phosphorylation of Thr1479 was determined by using the
phospho-specific antibody for detection of the phosphorylated
Thr1479 residue of LRP6. The results showed that the purified
CK1e directly phosphorylated Thr1479 in the GST-LRP6 mini
construct (Fig. 5B). Treatment with TPA dose-dependently in-
creased CK1e kinase activity (Fig. 5C), while CK1e-induced
LRP6 phosphorylation at Thr1479 was strongly inhibited by a
specific CK1 inhibitor, PF670462 (Fig. 5B). Additionally, TPA
rescued the inhibitory effect of PF670462 on the kinase activity
of CK1e (Fig. 5D). These results indicate that Thr1479 residue of
LRP6 is a CK1e phosphorylation site and TPA could enhance
the kinase activity of CK1e.
TPA Enhances the Level of Cytosolic β-Catenin in a CK1e/δ-Dependent
Fashion. To test whether TPA affects the level of cytosolic
β-catenin in a CK1e/δ-dependent fashion, HEK293T cells were
transfected with wild-type CK1e or CK1δ and dominant negative
mutant of CK1e or CK1δ, respectively. Treatment with TPA
increased cytosolic β-catenin level in the presence of either CK1e
or CK1δ in a time-dependent manner (Fig. 6A), while dominant
negative mutants of CK1e of CK1δ did not have discernable
effects on TPA-induced cytosolic β-catenin accumulation (Fig. 6B).
Fig. 5. CK1e phosphorylates LRP6 at Thr1479 in vitro and TPA enhances the kinase activity of CK1e. (A) The amino acid sequences of the LRP6 intracellular
region (residues 1470–1510) used in this study. Thr1479 residue is indicated by red. (B) The recombinant CK1e phosphorylates Thr1479 of GST-LRP6 mini
fragment in vitro, and TPA enhances CK1e kinase activity. GST-LRP6 mini fragment fusion protein was incubated with recombinant CK1e in the presence
of 200 μM ATP with or without 160 μM TPA or 2 μM PF670462 as indicated. The detection of the phosphorylation of Thr1479 was performed by im-
munoblotting using an anti–phospho-LRP6 (Thr1479) antibody. Thr1479 phosphorylation levels were quantitated by densitometry and normalized to
GST-LRP6 mini levels. *P < 0.05, **P < 0.01 versus the corresponding vehicle control (Student’s t test, n = 3). Quantitated results are displayed (Right). (C )
TPA potentiated the kinase activity of CK1e in a dose-dependent manner. The GST-LRP6 mini fusion protein was incubated with CK1e in the absence or
presence of the indicated concentrations of TPA. (D) TPA rescued the inhibitory effect of PF670462 on the kinase activity of CK1e. The GST-LRP6 mini
fusion protein was incubated with CK1e in the absence or presence of 2 μM PF670462 or the indicated amounts of TPA. Thr1479 phosphorylation of GST-
LRP6 mini was measured by immunoblotting using anti–phospho-LRP6 (Thr1479) antibody, indicated by p-LRP6 (Thr1479). Phosphorylation of Thr1479 is
indicated by an asterisk.
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In addition, treatment with the CK1e/δ inhibitor SR3029 blocked
TPA-induced cytosolic β-catenin accumulation in HEK293T and
UACC903 cells (Fig. 6C). Notably, TPA increased nuclear locali-
zation of β-catenin in melanoma UACC903 cells, and a higher level
of nuclear β-catenin was observed in response to TPA treatment in
the cells transfected with CK1e expression vector (Fig. 6D).
TPA Increases the Association of β-Catenin with TCF4E in a CK1e/
δ-Dependent Way. Given that TCF4 is a major player in Wnt/
β-catenin signaling in mouse skin carcinogenesis (44), we spec-
ulated that TPA stimulation may increase β-catenin and TCF4E
protein–protein interaction in a CK1e/δ-dependent way, finally
leading to the transcriptional activation of Wnt target genes. To
confirm this hypothesis, HEK293T or UACC903 cells were
transfected with the vectors encoding Flag-tagged versions of
wild-type and dominant negative mutants of CK1e or CK1δ,
respectively. Whole-cell lysates were immunoprecipitated with
anti–β-catenin antibody after treatment with TPA for 24 h. The
coimmunoprecipitation results showed that TPA stimulation
promotes the association of β-catenin with TCF4E in both
HEK293T and UACC903 cells (SI Appendix, Fig. S7 A–D). A
stronger interaction between β-catenin and TCF4E was observed
in the response to TPA in cells transfected with wild-type CK1e
or CK1δ, but not in cells transfected with dominant negative
mutants of CK1e or CK1δ (SI Appendix, Fig. S7 A–D). These
results indicate that CK1e/δ may mediate TPA-induced increase
in the interaction between β-catenin and TCF4E.
We next used a pDKK4-Luc reporter to evaluate whether
TPA-induced transcriptional activity is associated with the in-
teractions among β-catenin, TCF4E, and CK1e/δ in the nucleus.
The pDKK4-Luc reporter was constructed by cloning the DKK4
promoter region, which contains five putative TCF-binding sites,
into a luciferase reporter vector (SI Appendix, Fig. S7E).
DKK4 is a target gene of Wnt/β-catenin signaling. The activation
of a pDKK4-Luc reporter gene requires the simultaneous pres-
ence of β-catenin and LEF1, while β-catenin or LEF1 alone has a
moderate effect on its transcriptional activity (47). Consistently,
cotransfection of a pDKK4-Luc reporter with β-catenin and
TCF4E into HEK293T cells highly induced its transcriptional
activity, and the presence of CK1e further enhanced this effect
(SI Appendix, Fig. S7F). TPA dramatically increased DKK4
promoter transcription mediated by β-catenin/TCF4E or β-catenin/
TCF4E/CK1e. Treatment with SR3029 abrogated the TPA-induced
effect (SI Appendix, Fig. S7F). Together, these results suggest that
TPA-induced interaction among β-catenin, TCF4E, and CK1e/δ may
contribute to the transcriptional activation of Wnt target genes.
TPA Increases Expression of Wnt Target Genes. Activation of Wnt/
β-catenin signaling up-regulates the transcription of many genes.
CD44, cyclin D1, and DKK1 are established target genes of the
Wnt/β-catenin pathway (2). Real-time PCR was employed to
assess the effects of TPA on the expression of these Wnt target
genes. In HEK293T and UACC903 cells, treatment with TPA
(10 nM) markedly increased CD44 (SI Appendix, Fig. S8 A and D),
cyclin D1 (SI Appendix, Fig. S8 B and E), and DKK1 (SI Appendix,
Fig. S8 C and F) mRNA expression, while the CK1e/δ inhibitor
SR3029 dose-dependently abrogated the TPA-induced effects.
SR3029 Suppresses TPA-Induced Skin Tumor Formation in Vivo via
Blockade of Wnt/β-Catenin Signaling in Mouse Skin Two-Stage
Chemical Carcinogenesis. To determine whether blocking CK1e/δ
activity can suppress TPA-induced skin tumor formation in vivo,
we tested the antitumor efficacy of SR3029, a highly selective
dual CK1e/δ inhibitor, in the DMBA/TPA skin carcinogenesis
mouse model. Mice were initiated with DMBA, followed by
twice weekly applications of TPA (33), along with topical ap-
plication of either acetone vehicle or SR3029 immediately before
the TPA application. The first papillomas appeared at 6 wk after
TPA treatment, and the number of papillomas steadily in-
creased, reaching ∼18 tumors per mouse after 18 wk (Fig. 7 A
and B). In the group treated with TPA-SR3029, the first tumors
were observed at 8 wk, the tumors grew much more slowly than
those in control group, and the average number of tumors per
mouse was 4.9 after 18 wk (Fig. 7C). Histological analyses
showed that SR3029 treatment reduced the number of Ki-67–
positive cells in comparison with the controls, indicative of de-
creased tumor cell proliferation (Fig. 7D).
Immunohistochemical staining revealed that DMBA/TPA-
induced tumors expressed high levels of CK1e, CK1δ, active
β-catenin, and total β-catenin, while SR3029 treatment de-
creased their expression (Fig. 7D). The immunoblot results
showed that SR3029-treated tumors displayed decreased levels
of LRP6, CK1e, CK1δ, and active and total β-catenin compared
with TPA-treated tumors (Fig. 7E). Marked reductions in the
mRNA expression levels of the Wnt target genes CD44, cyclin
D1, and Fosb were observed in SR3029-treated tumors (Fig. 7F).
Fig. 6. TPA enhances the level of cytosolic β-catenin in a CK1e/δ-dependent fashion. (A) HEK293T cells were transfected with empty vector and an expression
plasmid for CK1e or CK1δ. The cells were incubated with 10 nM TPA for the indicated time periods. Cytosolic β-catenin (β-cat) was prepared as described in
Materials and Methods. The β-catenin expression level was detected by immunoblotting. (B) Similar to A except that dominant negative CK1e or CK1δ expression
vectors (CK1e DN or CK1δ DN) were used. (C) HEK293T and UACC903 cells were incubated with 10 nM TPA in the presence or absence of 60 nM SR3029. Cytosolic
β-catenin was prepared, and immunoblotting was used to detect β-catenin and GAPDH expression. The cytosolic β-catenin levels were quantified by densitometry
and normalized to GAPDH. *P < 0.05, **P < 0.01 versus vehicle control (Student’s t test, n = 3). Quantitated results are displayed (Bottom). (D) UACC903 cells
transfected with empty vector and CK1e expression plasmid were treated with 10 nM TPA for 6 h. Nuclear extracts were prepared using a Subcellular Protein
Fractionation Kit according to the manufacturer’s instructions. Fractions were analyzed by immunoblotting using the indicated antibodies. Asterisk indicates Flag-
tagged CK1e and an arrow indicates endogenous CK1e. Protein levels were quantified by densitometry and normalized to Lamin B1.
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These results indicate that SR3029 suppressed murine skin tu-
morigenesis induced by DMBA/TPA, probably via blocking the
Wnt/β-catenin signaling cascade.
Discussion
TPA is a well-known tumor promoter in two-stage mouse skin
carcinogenesis. The Wnt/β-catenin signaling pathway has been
shown to be constitutively activated in DMBA/TPA-induced skin
tumors (43, 44). However, it is not clear how this pathway is
activated in response to DMBA/TPA treatment. In the present
study, we demonstrated that TPA could enhance Wnt/β-catenin
signaling in a CK1e/δ-dependent manner. TPA stabilized CK1 by
inhibiting the ubiquitin-proteasome degradation system, en-
hanced its kinase activity, and induced phosphorylation of LRP6,
which may trigger the formation of CK1e–LRP6–axin1 complex,
leading to an increase in the cytosolic β-catenin. Moreover, TPA
could increase β-catenin and TCF4E protein-protein interaction
in a CK1e/δ-dependent way, finally resulting in the activation of
Wnt target genes. Importantly, treatment with a highly selective
CK1e/δ inhibitor SR3029 suppressed TPA-induced skin tumor
formation in vivo, probably through blocking Wnt/β-catenin
signaling. Taken together, our results define a pathway by which
TPA can activate the Wnt/β-catenin signaling cascade. This
pathway may play an important role in the tumor-promoting
activity of TPA in mouse skin carcinogenesis.
Binding of Wnt ligand to the Fzd receptor and coreceptor
LRP6 triggers recruitment of the scaffold protein Dvl to the
plasma membrane (3). Dvl promotes LRP6 aggregation and
phosphorylation at Thr1479 by CK1γ (7, 48). This phosphory-
lation event facilitates recruitment of the negative regulator axin
to the plasma membrane. Subsequently, axin-mediated β-catenin
phosphorylation and degradation is inhibited, allowing accumu-
lation of β-catenin (9). Our results imply that TPA treatment can
bypass the requirement for a Wnt–Fzd–Dvl complex. TPA sta-
bilized CK1e, enhanced its kinase activity, and induced phos-
phorylation of LRP6 at Thr1479 and Ser1490. Our results provide
direct evidence that the Thr1479 residue of LRP6 is a CK1e
phosphorylation site. While Ser1490 does not serve as a direct
substrate for CK1, TPA could induce phosphorylation of LRP6 at
Ser1490 via activation of ERK MAP kinases (8, 46). Our results
suggest that the presence of CK1e may enhance TPA-induced
phosphorylation at Ser1490 by ERK. It is reasonable that TPA-
induced phosphorylation of LRP6 facilitates the formation of a
CK1e–LRP6–axin complex by recruiting axin to the plasma mem-
brane, leading to cytosolic accumulation of β-catenin.
Relatively little is known concerning the mechanisms involved
in regulating the expression and activity of CK1 isoforms. The
CK1δ and CK1e isoforms are autorepressed enzymes. Their ki-
nase activities can be regulated by inhibitory autophosphor-
ylation at their C-terminal regions (11–13). Recently, the
DEAD-box RNA helicase DDX3 was identified as a regulator
Fig. 7. SR3029 suppresses TPA-induced skin tumor formation in vivo via blockade of Wnt/β-catenin signaling in mouse skin two-stage chemical carcino-
genesis. Fifteen mice per group were initiated with DMBA, followed by repetitive applications of TPA alone or together with SR3029 in acetone twice a week
for 18 wk. (A) Images of tumors from SR3029-untreated group and SR3029-treated groups. (B) The average number of papillomas per mouse at the 18th wk
of TPA administration in the SR3029-untreated group and the SR3029-treated group are compared (Student’s t test, n = 15). (C) The average number of
papillomas per mouse at the indicated times in SR3029-untreated group and SR3029-treated group are shown. The results are presented as mean ± SD. (D)
Hematoxylin/eosin staining and immunohistochemistry staining using antibodies specific for Ki-67, β-catenin, active β-catenin, CK1e, and CK1δ. (Scale bars:
100 μm.) (E) Expression levels of β-catenin, active β-catenin, CK1e, CK1δ, and LRP6 in tumor samples were visualized after immunoblotting. (F) The mRNA
expression levels of CD44, cyclin D1, and Fosb in tumor tissues were quantitated by real-time PCR. The results are shown as mean ± SD from three independent
experiments (**P < 0.01, Student’s t test, n = 8).
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of the Wnt/β-catenin signaling pathway by acting as a regulatory
subunit of CK1e in aWnt-dependent manner (49). It binds to CK1e,
directly stimulates its kinase activity, and promotes phosphorylation
of Dvl, resulting in stabilization of β-catenin. Our study demon-
strated that TPA exerts multiple actions on CK1e/δ and CK1e/
δ-mediated Wnt signaling. First, TPA induces intracellular accu-
mulation of CK1e and CK1δ by reducing their ubiquitination. This
effect of TPA was observed when CK1e and CK1δ were expressed
at physiological or supraphysiological levels. Second, TPA enhances
the kinase activity of CK1e. Third, TPA enhances the association of
CK1e with LPR6, thus promoting LRP6 phosphorylation. Fourth,
TPA can increase the interaction between β-catenin and TCF4E in
a CK1e/δ-dependent way. In addition, in vitro kinase assays showed
that TPA could rescue the inhibitory effect of PF670462 on the
kinase activity of CK1e (Fig. 5D). Consistently, the CK1e/δ inhibitor
SR3029 exerts an inhibitory effect on TPA-induced cytosolic
β-catenin accumulation (Fig. 6C). Moreover, TPA has been shown
to block the ubiquitination of CK1e and CK1δ (Fig. 3E). These
results imply that TPA may directly interact with CK1e/δ. However,
the dominant negative forms of CK1e/δ could not respond to TPA
in the ubiquitination assay (SI Appendix, Fig. S5B), suggesting that
the physical interaction of TPA with CK1e/δ requires autophos-
phorylation of CK1e/δ. It is very interesting to further characterize the
molecular mechanism by which TPA or other phorbol esters activate
Wnt signaling in a CK1e/δ-dependent manner.
TPA effectively activates PKC by mimicking its physiologic
ligand diacylglycerol (DAG) (50). PKC isozymes can be classified
into three subgroups based on differences in sequence homology
and biochemical properties: the Ca2+- and DAG-dependent con-
ventional PKC (cPKCα, βI, βII, and γ), the DAG-dependent novel
PKC (nPKCδ, θ, e, and η), and the Ca2+- and DAG-independent
atypical PKC (aPKCι and ζ) (22). It is well-documented that PKC
isozymes are implicated in the regulation of the Wnt signaling
pathway. Different PKC isozymes can exert opposite effects on
Wnt/β-catenin signaling. PKCα and PKCδ could negatively mod-
ulate Wnt/β-catenin signaling by regulating β-catenin stability,
whereas PKCe and PKCζ play important roles in the positive reg-
ulation of the Wnt/β-catenin pathway (51, 52). We tested effects of
some PKC modulators on Wnt signaling in the presence or absence
of CK1e or CK1δ. Strikingly, none of three PKC activators stimu-
lated the activation of Wnt/β-catenin signaling in cells transfected
with expression vectors encoding CK1e or CK1δ. Also, two PKC
inhibitors do not influence Wnt signaling in the presence of CK1e
or CK1δ. These results suggest that PKC may not be involved in
CK1-mediated activation of Wnt signaling in response to TPA.
CK1e and CK1δ are implicated in the control of the mam-
malian circadian clock by phosphorylating core clock proteins
(53). It is interesting to speculate that TPA may affect the cir-
cadian period via a CK1e/δ-dependent manner. A previous study
reported that TPA could advance the hamster circadian rhythms
(54). In NIH 3T3 fibroblasts, TPA treatment has been shown to
induce the circadian oscillation of expression of various clock
and clock-related genes (55). Future studies are needed to in-
vestigate the role of CK1e/δ in TPA-mediated circadian rhythms.
Increasing evidence has implicated CK1e/δ as positive regulators
of Wnt/β-catenin signaling (11, 13). However, the roles of CK1e/δ in
human cancer are still poorly understood. CK1e expression has been
shown to be up-regulated in adenoid cystic carcinomas of the sali-
vary gland, in epithelial ovarian cancer, in tumors of brain, head and
neck, kidney, bladder, lung, prostate, and salivary gland, and in
leukemia, melanoma, and seminoma (11). Elevated protein levels of
CK1δ and CK1e were also observed in tumor cells of grade 3 ductal
pancreatic carcinomas (56). Rosenberg et al. (57) recently identified
CK1δ as an efficacious therapeutic target with potential for clinical
relevance in a subset of breast cancers. Knockdown of CK1δ, or
treatment with a highly selective CK1e/δ inhibitor SR3029, induced
apoptosis of CK1δ-expressing breast tumor cells and tumor re-
gression in orthotopic models of triple-negative breast cancer, in-
cluding patient-derived xenografts, and in HER2+ breast cancer
models. A very recent study demonstrated that CK1e/δ is a novel
therapeutic target in chronic lymphocytic leukemia (CLL). The
CK1e/δ inhibitor PF-670462 significantly blocked microenviron-
mental interactions of CLL cells and delayed leukemia development
and progression in the Eμ-TCL1 mouse model (58). In this study,
CK1e and CK1δ have been identified as distinctive intracellular
targets of tumor-promoting TPA. Expression of CK1e and CK1δ
was required for TPA-induced activation of Wnt/β-catenin signaling.
Importantly, a dual CK1e/δ inhibitor SR3029 potently inhibited
TPA-induced tumorigenesis by blocking Wnt/β-catenin signaling in
a mouse skin cancer model. Collectively, these results indicated that
CK1e and CK1δ may be therapeutic targets for cancer drug de-
velopment, especially for cancers with Wnt pathway activation.
In summary, our study identified a mechanism by which TPA
activates Wnt/β-catenin signaling. TPA could stabilize CK1e,
enhance its kinase activity, and induce phosphorylation of LRP6,
resulting in the formation of CK1e–LRP6–axin1 complex, which
may bypass the requirement of Wnt–Fzd–Dvl complex. TPA also
enhanced the interaction between β-catenin and TCF4E in a
CK1e/δ-dependent way, and finally led to activation of the Wnt/
β-catenin pathway. Our findings reveal a pathway by which
phorbol esters such as TPA activate the Wnt/β-catenin signaling
cascade. This pathway may represent a common mechanism for
the tumor-promoting activity of some carcinogenic agents.
Materials and Methods
The cell lines and plasmids used in this study are described in SI Appendix,
Materials and Methods. Details of in vitro kinase assay, luciferase reporter gene
assay, subcellular fractionations, coimmunoprecipitation, quantitative real-time
PCR analyses, two-stage skin carcinogenesis assays, histological analyses, and
statistical analyses are provided in SI Appendix, Materials and Methods. All
animal experiments were performed according to the protocols approved by
the Administrative Committee on Animal Research of Shenzhen University.
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